Coherus BioSciences (CHRS) : Traders are bullish on Coherus BioSciences (CHRS) as it has outperformed the S&P 500 by a wide margin of 3.64% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.48%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.03% in the last 1 week, and is up 1.54% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 3.17% and the 50-Day Moving Average is 13.14%.The 200 Day SMA reached 48.56% Coherus Biosciences, Inc. is up 98.97% in the last 3-month period. Year-to-Date the stock performance stands at 34.93%.
Coherus BioSciences (CHRS) : The highest short term price target forecast on Coherus BioSciences (CHRS) is $46 and the lowest target price is $43. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $44.67 with a standard deviation of $1.53.
For the current week, the company shares have a recommendation consensus of Buy. Coherus BioSciences (NASDAQ:CHRS): The stock opened at $30.27 and touched an intraday high of $31.98 on Friday. During the day, the stock corrected to an intraday low of $29.83, however, the bulls stepped in and pushed the price higher to close in the green at $30.98 with a gain of 2.53% for the day. The total traded volume for the day was 1,507,089. The stock had closed at $30.98 in the previous trading session.
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Companys clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF), and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Companys product pipeline includes anti-TNF product candidate, CHS-0214, an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials, and anti-TNF product candidate, CHS-1420, an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate, CHS-1701, a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.